Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. The lack of head-to-head trials complicates treatment prioritization, ...
Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra ® (resmetirom) as the foundational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results